MIR139 is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML). However, the tumor-suppressing activities of miR-139 and molecular mechanisms of MIR139-silencing remain largely unknown. Here, we studied the poorly prognostic MLL-AF9 fusion protein-expressing AML. We show that MLL-AF9 expression in hematopoietic precursors caused epigenetic silencing of MIR139, whereas overexpression of MIR139 inhibited in vitro and in vivo AML outgrowth. We identified novel miR-139 targets that mediate the tumor-suppressing activities of miR-139 in MLL-AF9 AML. We revealed that two enhancer regions control MIR139 expression and found that the polycomb repressive complex 2 (PRC2) downstream of MLL-AF9 epigenetically silenced MIR139 in AML. Finally, a genome-wide CRISPR-Cas9 knockout screen revealed RNA Polymerase 2 Subunit M (POLR2M) as a novel MIR139-regulatory factor. Our findings elucidate the molecular control of tumor suppressor MIR139 and reveal a role for POLR2M in the MIR139-silencing mechanism, downstream of MLL-AF9 and PRC2 in AML. In addition, we confirmed these findings in human AML cell lines with different oncogenic aberrations, suggesting that this is a more common oncogenic mechanism in AML. Our results may pave the way for new targeted therapy in AML.

Center for Proteomics and Metabolomics Leiden University Medical Center Leiden the Netherlands

Childhood Leukemia Investigation Prague Department of Pediatric Haematology and Oncology 2nd Faculty of Medicine Charles University Prague Prague Czech Republic

Department of Hemato Oncology Institute of Molecular Genetics of the Czech Academy of Sciences Prague Czech Republic

Erasmus MC University Medical Center Rotterdam Center for Biomics Rotterdam the Netherlands

Erasmus MC University Medical Center Rotterdam Department of Cell Biology Rotterdam the Netherlands

Erasmus MC University Medical Center Rotterdam Department of Hematology Rotterdam the Netherlands

Erasmus MC University Medical Center Rotterdam Department of Immunology Rotterdam the Netherlands

See more in PubMed

Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012;7:283–301. PubMed PMC

Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96. PubMed PMC

Winters AC, Bernt KM. MLL-rearranged leukemias-an update on science and clinical approaches. Front Pediatr. 2017;5:4. PubMed PMC

Steinhilber D, Marschalek R. How to effectively treat acute leukemia patients bearing MLL-rearrangements? Biochem Pharm. 2018;147:183–90. PubMed

Kotani S, Yoda A, Kon A, Kataoka K, Ochi Y, Shiozawa Y, et al. Molecular pathogenesis of disease progression in MLL-rearranged AML. Leukemia. 2019;33:612–24. PubMed PMC

Xu J, Li L, Xiong J, denDekker A, Ye A, Karatas H, et al. MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. Cell Discov. 2016;2:16008. PubMed PMC

Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive aml expressing EMT-related genes linked to poor outcome. Cancer Cell. 2016;30:43–58. PubMed

Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, Huls G, et al. MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia. 2013;27:1116–26. PubMed

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33. PubMed PMC

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838. PubMed

Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111:5078–85. PubMed

Alemdehy MF, Haanstra JR, de Looper HW, van Strien PM, Verhagen-Oldenampsen J, Caljouw Y, et al. ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation. Blood. 2015;125:3937–48. PubMed

Emmrich S, Engeland F, El-Khatib M, Henke K, Obulkasim A, Schoning J, et al. miR-139-5p controls translation in myeloid leukemia through EIF4G2. Oncogene. 2016;35:1822–31. PubMed

Krowiorz K, Ruschmann J, Lai C, Ngom M, Maetzig T, Martins V, et al. MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia. Blood Cancer J. 2016;6:e508. PubMed PMC

Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology. 2011;141:2076–2087 e2076. PubMed

Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R. Polycomb group (PcG) proteins and human cancers: multifaceted functions and therapeutic implications. Med Res Rev. 2015;35:1220–67. PubMed PMC

Huang X, Yan J, Zhang M, Wang Y, Chen Y, Fu X, et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell. 2018;175:186–199 e119. PubMed

Zhang H, Zhu D, Zhang Z, Kaluz S, Yu B, Devi NS, et al. EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. Oncogene. 2020;39:1041–1048. PubMed PMC

van Mierlo G, Veenstra GJC, Vermeulen M, Marks H. The complexity of PRC2 subcomplexes. Trends Cell Biol. 2019;29(Aug):660–71. PubMed

Laugesen A, Hojfeldt JW, Helin K. Molecular mechanisms directing PRC2 recruitment and H3K27 methylation. Mol Cell. 2019;74(Apr 4):8–18. PubMed PMC

Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein. Genes Dev. 2002;16:2893–905. PubMed PMC

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci USA. 2012;109:5028–5033. PubMed PMC

Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, et al. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model. Exp Hematol. 2015;43:930–935 e936. PubMed PMC

Aranda S, Mas G, Di, Croce L. Regulation of gene transcription by polycomb proteins. Sci Adv. 2015;1:e1500737. PubMed PMC

Hope JH, Zhao M, Stairiker CJ, Kiernan C, Alison CJ, Mueller YM, et al. MicroRNA-139 expression is dispensable for the generation of influenza-specific CD8+ T cell responses. J Immunol 2021 In Press. PubMed PMC

van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26:1908–1975. PubMed PMC

Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011;117:6912–6922. PubMed PMC

Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, Kersey JH. Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood. 2004;103:1823–1828. PubMed

Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125:346–357. PubMed PMC

Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, et al. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015;27:589–602. PubMed PMC

Lara-Astiaso D, Weiner A, Lorenzo-Vivas E, Zaretsky I, Jaitin DA, David E, et al. Immunogenetics. Chromatin state dynamics during blood formation. Science. 2014;345:943–949. PubMed PMC

Volk A, Liang K, Suraneni P, Li X, Zhao J, Bulic M, et al. A CHAF1B-dependent molecular switch in hematopoiesis and leukemia pathogenesis. Cancer Cell. 2018;34:707–723 e707. PubMed PMC

Ordonez R, Martinez-Calle N, Agirre X, Prosper F. DNA methylation of enhancer elements in myeloid neoplasms: think outside the promoters? Cancers (Basel) 2019;11:1424. PubMed PMC

Wang X, Paucek RD, Gooding AR, Brown ZZ, Ge EJ, Muir TW, et al. Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA. Nat Struct Mol Biol. 2017;24:1028–1038. PubMed PMC

Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783–784. PubMed PMC

DeLaney E, Luse DS. Gdown1 associates efficiently with RNA polymerase II after promoter clearance and displaces TFIIF during transcript elongation. PLoS One. 2016;11:e0163649. PubMed PMC

Guo J, Turek ME, Price DH. Regulation of RNA polymerase II termination by phosphorylation of Gdown1. J Biol Chem. 2014;289:12657–12665. PubMed PMC

Jishage M, Malik S, Wagner U, Uberheide B, Ishihama Y, Hu X, et al. Transcriptional regulation by Pol II(G) involving mediator and competitive interactions of Gdown1 and TFIIF with Pol II. Mol Cell. 2012;45:51–63. PubMed PMC

Ni ZZ, He JK, Tang X, Tao Z, Zhang Y, Xie B. Identification of ELAVL1 gene and miRNA-139-3p involved in the aggressiveness of NSCLC. Eur Rev Med Pharm Sci. 2020;24:9453–9464. PubMed

Kohram F, Fallah P, Shamsara M, Bolandi Z, Rassoulzadegan M, Soleimani M, et al. Cell type-dependent functions of microRNA-92a. J Cell Biochem. 2018;119:5798–5804. PubMed

Hsin JP, Lu Y, Loeb GB, Leslie CS, Rudensky AY. The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. Nat Immunol. 2018;19:1137–1145. PubMed PMC

Nussbacher JK, Yeo GW. Systematic discovery of RNA binding proteins that regulate MicroRNA levels. Mol Cell. 2018;69:1005–1016 e1007. PubMed PMC

Shi J, Wang E, Zuber J, Rappaport A, Taylor M, Johns C, et al. The polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene. 2013;32:930–938. PubMed PMC

Ma J, Zhang J, Weng YC, Wang JC. EZH2-mediated microRNA-139-5p regulates epithelial-mesenchymal transition and lymph node metastasis of pancreatic cancer. Mol Cells. 2018;41:868–880. PubMed PMC

Wu D, Wu F, Li B, Huang W, Wang D. EZH2 promotes the expression of LPA1 by mediating microRNA-139 promoter methylation to accelerate the development of ovarian cancer. Cancer Cell Int. 2020;20:551. PubMed PMC

Lehtinen L, Vainio P, Wikman H, Reemts J, Hilvo M, Issa R, et al. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. J Pathol. 2012;226:674–686. PubMed

He N, Zheng H, Li P, Zhao Y, Zhang W, Song F, et al. miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PLoS One. 2014;9:e102093. PubMed PMC

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004;304:1164–1166. PubMed

Ku M, MacKinnon RN, Wall M, Narayan N, Walkley C, Cheng HC, et al. Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly. Sci Rep. 2019;9:7050. PubMed PMC

Yao Y, Shao J, Wu J, Zhang Q, Wang J, Xiao D, et al. The functional variant in the 3’UTR of PTPRT with the risk of esophageal squamous cell carcinoma in a chinese population. Cell Physiol Biochem. 2015;36:306–314. PubMed

Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117:5701–5709. PubMed PMC

Sen M, Kindsfather A, Danilova L, Zhang F, Colombo R, LaPorte MG, et al. PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies. Epigenetics. 2020;15:604–617. PubMed PMC

Aigner P, Mizutani T, Horvath J, Eder T, Heber S, Lind K, et al. STAT3beta is a tumor suppressor in acute myeloid leukemia. Blood Adv. 2019;3:1989–2002. PubMed PMC

Tai HH, Tong M, Ding Y. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat. 2007;83:203–208. PubMed PMC

Yuniati L, Scheijen B, van der Meer LT, van Leeuwen FN. Tumor suppressors BTG1 and BTG2: beyond growth control. J Cell Physiol. 2019;234:5379–5389. PubMed PMC

Kleinsimon S, Longmuss E, Rolff J, Jager S, Eggert A, Delebinski C, et al. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. Sci Rep. 2018;8:5750. PubMed PMC

Wang Y, Jin W, Jia X, Luo R, Tan Y, Zhu X, et al. Transcriptional repression of CDKN2D by PML/RARalpha contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells. Cell Death Dis. 2014;5:e1431. PubMed PMC

Grespi F, Soratroi C, Krumschnabel G, Sohm B, Ploner C, Geley S, et al. BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent protein synthesis. Cell Death Differ. 2010;17:1672–1683. PubMed PMC

Yang J, Sun L, Han J, Zheng W, Peng W. DUSP1/MKP-1 regulates proliferation and apoptosis in keratinocytes through the ERK/Elk-1/Egr-1 signaling pathway. Life Sci. 2019;223:47–53. PubMed

Diaz-Guerra M, Rivas C, Esteban M. Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. Virology. 1997;236:354–363. PubMed

Ishii K, Ishiai M, Morimoto H, Kanatsu-Shinohara M, Niwa O, Takata M, et al. The Trp53-Trp53inp1-Tnfrsf10b pathway regulates the radiation response of mouse spermatogonial stem cells. Stem Cell Rep. 2014;3:676–689. PubMed PMC

Baker SJ. Small unstable apoptotic protein, an apoptosis-associated protein, suppresses proliferation of myeloid cells. Cancer Res. 2003;63:705–712. PubMed

Mao R, Yang R, Chen X, Harhaj EW, Wang X, Fan Y. Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses. Cell Mol Immunol. 2017;14:412–422. PubMed PMC

Tang F, Zhang Y, Huang QQ, Qian MM, Li ZX, Li YJ, et al. Genome-wide identification and analysis of enhancer-regulated microRNAs across 31 human cancers. Front Genet. 2020;11:644. PubMed PMC

Suzuki HI, Young RA, Sharp PA. Super-enhancer-mediated RNA processing revealed by integrative MicroRNA network analysis. Cell. 2017;168:1000–1014 e1015. PubMed PMC

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. PubMed

Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. Science. 2004;306:1574–1577. PubMed

Jishage M, Ito K, Chu CS, Wang X, Yamaji M, Roeder RG. Transcriptional down-regulation of metabolic genes by Gdown1 ablation induces quiescent cell re-entry into the cell cycle. Genes Dev. 2020;34:767–784. PubMed PMC

Jishage M, Yu X, Shi Y, Ganesan SJ, Chen WY, Sali A, et al. Architecture of Pol II(G) and molecular mechanism of transcription regulation by Gdown1. Nat Struct Mol Biol. 2018;25:859–867. PubMed PMC

Liu J, Wu X, Zhang H, Pfeifer GP, Lu Q. Dynamics of RNA polymerase II pausing and bivalent histone h3 methylation during neuronal differentiation in brain development. Cell Rep. 2017;20:1307–1318. PubMed PMC

Mantsoki A, Devailly G, Joshi A. Dynamics of promoter bivalency and RNAP II pausing in mouse stem and differentiated cells. BMC Dev Biol. 2018;18:2. PubMed PMC

Min IM, Waterfall JJ, Core LJ, Munroe RJ, Schimenti J, Lis JT. Regulating RNA polymerase pausing and transcription elongation in embryonic stem cells. Genes Dev. 2011;25:742–754. PubMed PMC

Henriques T, Scruggs BS, Inouye MO, Muse GW, Williams LH, Burkholder AB, et al. Widespread transcriptional pausing and elongation control at enhancers. Genes Dev. 2018;32:26–41. PubMed PMC

Jishage M, Roeder RG. Regulation of hepatocyte cell cycle re-entry by RNA polymerase II-associated Gdown1. Cell Cycle. 2020;19:3222–3230. PubMed PMC